55464-76-1 Usage
Properties
1. Chemical compound
2. Used in the production of polymers
3. Crosslinking agent in coatings and adhesives
4. Colorless liquid
5. Sharp, pungent odor
6. Highly flammable
7. Used in synthesis of pharmaceuticals
8. Monomer in production of resins and plastics
9. Reactive chemical
10. Can cause irritation to skin, eyes, and respiratory system
11. Should be handled with care
12. Avoid contact with oxidizing agents
13. Store in a cool, well-ventilated area
14. Versatile with wide range of industrial applications
Specific content
Primarily used in production of polymers and as a crosslinking agent in coatings and adhesives
Used in synthesis of pharmaceuticals and as a monomer in production of resins and plastics
Should be handled with care as it can cause irritation to skin, eyes, and respiratory system
Important to avoid contact with oxidizing agents and store in cool, well-ventilated area
Highly flammable colorless liquid with sharp, pungent odor
Check Digit Verification of cas no
The CAS Registry Mumber 55464-76-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,5,4,6 and 4 respectively; the second part has 2 digits, 7 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 55464-76:
(7*5)+(6*5)+(5*4)+(4*6)+(3*4)+(2*7)+(1*6)=141
141 % 10 = 1
So 55464-76-1 is a valid CAS Registry Number.
InChI:InChI=1/C7H8O4/c1-2-5-11-7(10)4-3-6(8)9/h2-4H,1,5H2,(H,8,9)/b4-3+
55464-76-1Relevant articles and documents
DNA-TEMPLATED MACROCYCLE LIBRARY
-
Paragraph 00235; 00236, (2019/09/18)
The present invention provides nucleic acid templates (e.g., including orthogonal codon sets (e.g., codons from orthogonal codon sets depicted in Tables 5 or 7)) for DNA-templated methods of synthesizing, selecting, and amplifying compounds (e.g., polymers and/or small molecules) described herein. Also provided are novel macrocyclic compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, libraries, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing a disease (e.g., a disease associated with aberrant enzyme activity (e.g., aberrant protease and/or kinase activity (e.g., aberrant IDE activity)), impaired insulin signaling, or insulin resistance in a subject (e.g., a subject having diabetes). Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit aberrant protease activity (e.g., aberrant IDE activity).
